Enter Note Done
Go to previous page in this tab
Event
  • Engagement Session
  • Bookmark Icon
  • Rethinking DART Testing: Advancing Dev Tox NAMs Through Stakeholder Dialogue
  • Schedule
    Notes
  • Room 301‚ Convention Center
    Set Timezone


Chair: Connie Chen, HESI Global
Co-Chair: Julia Boos, Swiss Centre for Applied Human Toxicology, Switzerland

Primary Endorser: Reproductive and Developmental Toxicology Specialty Section


Endorser(s): In Vitro and Alternative Methods Specialty Section


Toxicity testing is entering a period of scientific and regulatory transition, with increasing interest in how human-relevant New Approach Methodologies (NAMs) can complement and, where appropriate, reduce reliance on animal-based studies. Standardized animal studies remain central to regulatory assessment because they provide integrated organism-level information on developmental and reproductive outcomes relevant to human health. However, these studies are resource-intensive, use substantial numbers of animals, and can be limited by species differences in toxicokinetics and toxicodynamics. These challenges are particularly pronounced in developmental and reproductive toxicology (DART), where toxicity reflects complex, dynamic processes involving precise timing, tissue interactions, and coordinated biological events.

Advances in mechanistic toxicology, stem-cell-based models, transcriptomics, in silico tools, and exposure modelling are creating new opportunities to assess developmental and reproductive toxicity using human-relevant NAMs. Modern toxicology provides growing mechanistic insight into how chemicals can perturb developmental and reproductive biology. Rather than relying only on apical outcomes, NAMs can contribute information on molecular and cellular perturbations, modes of action, and pathways relevant to adverse outcomes enabling more hypothesis-driven testing strategies. However, unlike a single guideline animal study, NAM-based approaches will likely require multiple complementary methods to capture the spatiotemporal complexity of development and achieve sufficient biological coverage. This raises key scientific and regulatory questions: Which developmental and reproductive processes need to be represented? What level of mechanistic detail is sufficient for decision-making? How should biological coverage, exposure, toxicokinetics, and systemic interactions be integrated? Should NAMs primarily be evaluated against current animal-study outcomes, or should future DART strategies be designed around human biology, mechanisms of toxicity, and clearly defined decision contexts?

Progress in this area will require early and sustained dialogue across stakeholder groups. Regulators, industry scientists, academic researchers, model developers, and clinicians share the goal of protecting reproductive and developmental health, but they may approach this goal with different expectations, constraints, and evidentiary needs. Regulators require reliable and interpretable evidence that is clearly linked to a defined context of use and suitable for decision-making. Industry needs approaches that are practical, scalable, and accepted within regulatory frameworks. Academic researchers and technology developers often focus on biological relevance, mechanistic understanding, and innovation, while clinicians can help ensure that testing strategies remain anchored in human developmental and reproductive biology. Without alignment on context of use, applicability domain, confidence criteria, and interpretation of results, scientifically promising NAMs may remain difficult to implement broadly.

Building on recent and ongoing workshops on developmental toxicity (Dev Tox) NAMs, this engagement session will provide an interactive forum to discuss how Dev Tox NAMs may contribute to safety assessment and decision-making in a pharmaceutical context. The international panel, representing academia, industry, regulatory science, and the clinical perspective, will discuss key considerations for NAM development, evaluation, and interpretation across different contexts of use within this pharmaceutical setting. These include biological and clinical relevance, relevance to human developmental outcomes and patient counselling, the level of mechanistic granularity needed, confidence in method performance, integration of exposure and toxicokinetic information, benchmarking against existing knowledge, and the potential role of tiered testing strategies. Audience engagement will be integrated throughout the session using live polling to capture perspectives on key scientific and regulatory questions, stimulate discussion, and identify areas of agreement and uncertainty. The session will conclude with an open Q&A discussion with all speakers, additional regulatory panelists and with the audience.

Overall, the session aims to foster cross-sector dialogue, clarify shared challenges across stakeholder groups and identify where further alignment is needed to support the development of scientifically robust, mechanism-informed approaches for DART-relevant NAMs.

Session and Activity Type
Presentations